Making real world evidence fit for purposeAlthough real world evidence (RWE) is a hot topic in pharma right now, many still question whether it Share XMaking real world evidence fit for purposehttps://pharmaphorum.com/views-analysis-market-access/making-real-world-evidence-fit-for-purpose/
The 4 biggest pharma market access stories of 2019What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive Share XThe 4 biggest pharma market access stories of 2019https://pharmaphorum.com/views-analysis-market-access/the-4-biggest-pharma-market-access-stories-of-2019/
An alternative set of metrics for the UK’s pricing and access dealLeela Barham takes a look at alternative ways pharma and the UK government could measure progress for the Share XAn alternative set of metrics for the UK’s pricing and access dealhttps://pharmaphorum.com/views-and-analysis/an-alternative-set-of-metrics-for-the-uks-pricing-and-access-deal/
Incorporating the patient voice from clinical development to commercialisationPatients increasingly want to be more involved in their healthcare, decisions about it and research towards its improvement, Share XIncorporating the patient voice from clinical development to commercialisationhttps://pharmaphorum.com/patients/incorporating-the-patient-voice-from-clinical-development-to-commercialisation/
NICE numbers at 20: trends in dealsNICE provides a downloadable excel file of details of Technology Appraisal (TAs) recommendations which can help explore trends Share XNICE numbers at 20: trends in dealshttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-trends-in-deals/
NICE numbers at 20 – a closer look at cancerThere has been continual interest in what the UK’s Health Technology Assessment (HTA) agency, the National Institute for Share XNICE numbers at 20 – a closer look at cancerhttps://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-a-closer-look-at-cancer/
Who could replace Sir Andrew Dillon at NICE?With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the Share XWho could replace Sir Andrew Dillon at NICE?https://pharmaphorum.com/views-and-analysis/who-could-replace-sir-andrew-dillon-at-nice/
NICE’s track record in cancer drugs: the impact of the CDF and interim fundingLeela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 Share XNICE’s track record in cancer drugs: the impact of the CDF and interim fundinghttps://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/
NICE numbers at 20Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed Share XNICE numbers at 20https://pharmaphorum.com/views-analysis-market-access/nice-numbers-20/
